Tag: Epizyme
Ipsen has completed the acquisition of the American company Epizyme
By Olivier Cheilan Published on 08/12/2022 at 6:02 p.m. (Boursier.com) —…
Ipsen: acquisition of Epizyme finalized – 08/15/2022 at 07:47
(CercleFinance.com) – Ipsen announced Friday evening the finalization of the agreement under which it acquired all of the outstanding shares of Epizyme at a price of 1.45 dollars per share…
Ipsen: acquisition of Epizyme finalized
(CercleFinance.com) – Ipsen announced Friday evening the finalization of the agreement under which it acquired all of the outstanding shares of Epizyme at a price of 1.45 dollars per share…
Ipsen has finalized the acquisition of the American company Epizyme specialized in oncology
Agefi – Dow Jones | On 08/12/22 at 17:58 | Updated on 08/12/22 at 18:04 Ipsen finalized the acquisition of the American company Epizyme specialized in oncology | Photo credits:…
Ipsen will acquire the American Epizyme – 06/27/2022 at 08:18
(AOF) – Ipsen has entered into a definitive merger agreement with Epizyme. The transaction has been unanimously approved by the respective boards of directors of Ipsen and Epizyme with expected…
Ipsen to launch a $247 million takeover bid for Epizyme, the action ebbs
PARIS (Agefi-Dow Jones)–The pharmaceutical laboratory Ipsen announced on Monday that it was preparing to launch a friendly takeover bid (OPA) targeting 100% of the capital of the American biopharmaceutical company…
The acquisition of Epizyme promising for Ipsen, but in the medium term
By acquiring Epizyme, Ipsen gets its hands on Tazverik (tazemetostat), an innovative anti-tumor (EZH2 inhibitor) which has already obtained approval from the FDA (American health authorities) and has benefited from…
Ipsen: The takeover of the American biotech Epizyme does not appeal to Ipsen shareholders
(BFM Bourse) – Once again, the price of the tricolor pharmaceutical group is declining on the announcement of an external growth operation. Ipsen has set its sights on Epizyme and…
Ipsen to launch a $247 million takeover bid for Epizyme, the action ebbs
(Update: analyst comments) PARIS (Agefi-Dow Jones)–The pharmaceutical laboratory Ipsen announced on Monday that it was preparing to launch a friendly takeover bid (OPA) targeting 100% of the capital of the…
Ipsen: agreement for the acquisition of Epizyme
(CercleFinance.com) – Ipsen announces that it has entered into a definitive agreement to acquire Epizyme, a biopharmaceutical company ‘committed to developing and delivering innovative treatments through new epigenetic drugs for…
Ipsen: Agreement for the acquisition of Epizyme
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
The acquisition of Epizyme promising for Ipsen, but in the medium term
Subscribe for 1€ Unlimited access to all advice More than 800 stocks listed in Paris and abroad screened. To buy ? Sale ? What course objective? Our experts engage and…